Knight Therapeutics’ regulatory submission of Niktimvo (axatilimab) in Brazil marks an important milestone in expanding access to novel therapies for chronic graft-versus-host disease (cGvHD) across Latin America. The filing reflects growing regional momentum in advanced immunology and transplant-related therapies, highlighting Brazil’s strategic importance as a key pharmaceutical market in the region, says GlobalData, a leading intelligence and productivity platform.

The submission to Brazil’s health regulatory authority seeks approval for axatilimab, a monoclonal antibody targeting colony-stimulating factor-1 receptor (CSF-1R), for the treatment of chronic GvHD. Chronic GvHD can involve multiple organ systems including the skin, liver, gastrointestinal tract, and lungs, and is associated with significant morbidity, impaired quality of life, and prolonged immunosuppressive therapy. While corticosteroids remain first-line therapy, a substantial proportion of patients require additional systemic treatment due to inadequate response or intolerance, underscoring the need for targeted biologic options.

Graysen Vigneux, Pharma Analyst at GlobalData, comments: “The Brazilian submission of axatilimab underscores the continued evolution of chronic GvHD management beyond corticosteroids and broad immunosuppressants. Targeted biologics such as CSF-1R inhibitors represent a more mechanism-driven approach, potentially improving outcomes in patients with persistent, treatment-resistant disease.”

Axatilimab’s differentiated mechanism of action may offer an additional therapeutic option in a space that has historically been limited, particularly for patients who fail to achieve an initial therapeutic response to traditional systemic therapy. Its expansion into Brazil could contribute to broader regional adoption trends across Latin America, depending on health technology assessment outcomes and inclusion in national formularies.

Vigneux concludes: “The submission also highlights the increasing globalization of specialty biologics, with companies seeking earlier penetration into emerging markets rather than sequential expansion following US or European launches. This approach may enhance lifecycle value while addressing unmet need in regions where access to advanced transplant therapies is evolving.”